BOTHELL, WA, Aug. 26, 2020 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc.(NASDAQ: COCP), (“Cocrystal” or the “Company”), a clinical stage biotechnology company discovering and developing novel antiviral therapeutics, announced today that, due to demand, the underwriter has agreed to increase the size of its previously announced public offering and purchase on a firm commitment basis 14,285,715 shares of common stock of the Company, at a price to the public of $1.05 per share, less underwriting discounts and commissions. The closing of the offering is expected to occur on or about August 31, 2020, subject to satisfaction of customary closing conditions.
Cocrystal Pharma Increases Previously Announced Bought Deal to $15.0 Million
Aug 27, 2020
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers